Lancet Infectious Diseases

The Lancet is a weekly peer-reviewed general medical journal. It is one of the world's best known, oldest, and most respected general medical journals. The Lancet was founded in 1823 by Thomas Wakley, an English surgeon who named it after the surgical instrument called a lancet, as well as after the term "lancet arch", a window with a sharp pointed arch, to indicate the "light of wisdom" or "to let in light". It publishes original research articles, review articles ("seminars" and "reviews"), editorials, book reviews, correspondence, as well as news features and case reports. The Lancet has been owned by Elsevier since 1991. As of 1995, the editor-in-chief is Richard Horton. The journal has editorial offices in London, New York, and Beijing. In the 2010 Journal Citation Reports, The Lancet s impact factor was ranked second among general medical journals, at 33.63, after The New England Journal of Medicine (53.48). The Lancet also has several speciality journals all bearing the parent title: The Lancet Neurology (neurology), The Lancet Oncology (oncology), and The Lancet Infectious Diseases (infectious diseases), all of which publish original research and reviews. These three

Publisher
Elsevier
History
1823-present
Impact factor
33.633 (2010)

Some content from Wikipedia, licensed under CC BY-SA

Diseases, Conditions, Syndromes

Team uncovers largest US outbreak of neurologic disease to date

The Lancet Infectious Diseases recently published the results of an observational study led by researchers on Children's Hospital Colorado Infectious Disease and Neurology teams, along with counterparts at the Centers for ...

Diseases, Conditions, Syndromes

Drug-resistant staph can spread easily in household environments

Once rare, the superbug methicillin-resistant Staphylococcus aureus (MRSA) infects hundreds of thousands of people in the U.S. each year and kills about 20,000. Antibiotic overuse has made MRSA more common and difficult to ...

Diseases, Conditions, Syndromes

Successful study of Swedish vaccine candidate against diarrhea

University of Gothenburg researchers have reported the first successful results of an oral, inactivated vaccine candidate ETVAX against enterotoxigenic E. coli diarrhea in a placebo-controlled phase I/II study in infants ...

page 1 from 24